Cover Image
市場調查報告書

慢性淋巴性白血病的全球市場:2016∼2020年

Global Chronic Lymphocytic Leukemia market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 359355
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
慢性淋巴性白血病的全球市場:2016∼2020年 Global Chronic Lymphocytic Leukemia market 2016-2020
出版日期: 2016年06月01日 內容資訊: 英文 78 Pages
簡介

白血病依據造血幹細胞的成熟度分為慢性和慢性,癌症依據 原發骨髓細胞分為淋巴性和骨髓性。全球慢性淋巴性白血病市場,預計2016∼2020年,以年複合成長率19.16%擴大。

本報告提供全球慢性淋巴性白血病市場相關調查,市場現狀及2016∼2022年的市場成長預測,市場規模,各地區趨勢,加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 疾病概要

  • 疾病的理解
  • 慢性淋巴性白血病的種類
  • 症狀
  • 診斷
  • 分期
  • 管理
  • 重要的購買標準

第6章 開發平台分析

第7章 市場情況

第8章 各給藥途徑市場區隔

  • 口服
  • 非口服

第9章 各分子市場區隔

  • 小分子
  • 生技藥品

第10章 各地區市場區隔

  • 各地區市場
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 推動市場的要素

第12章 促進要素的影響

第13章 市場課題

  • 治療費的高度
  • 化療和仿單標示外藥物
  • 藥物的副作用
  • 嚴格的法律規章指南

第14章 促進要素與課題的影響

第15章 市場趨勢

第16章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • F. Hoffmann-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • 其他值得注意的供應商

第17章 附錄

第18章 關於Technavio

圖表

目錄
Product Code: IRTNTR9378

About the Chronic Lymphocytic Leukemia (CLL) Therapeutics Market

Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia can be broadly classified into four types:

  • Acute myeloid (or myelogenous) leukemia (AML)
  • Chronic myeloid (or myelogenous) leukemia (CML)
  • Acute lymphocytic (or lymphoblastic) leukemia (ALL)
  • CLL

Technavio's analysts forecast the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global CLL therapeutics market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent CLL. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • F. Hoffman-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Gilead Sciences
  • Novartis
  • Johnson & Johnson

Other Prominent Vendors

  • Altor BioScience
  • Amgen
  • Arno Therapeutics
  • AstraZeneca
  • Bellicum Pharmaceuticals
  • Biogen
  • BioLineRx
  • Boston Biomedical
  • Celgene
  • Emergent BioSolutions
  • Genzyme
  • iDD biotech
  • Immunomedics
  • Infinity Pharmaceuticals
  • Innate Pharma
  • Karyopharm Therapeutics
  • Ligand Pharmaceuticals
  • MedImmune
  • Merck Sharp & Dohme
  • Molecular Templates Inc.
  • MorphoSys
  • Ono Pharmaceutical
  • Portola Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Sunesis Pharmaceuticals
  • TG Therapeutics
  • TheraMAB
  • XEME Biopharma
  • Xencor
  • ZIOPHARM Oncology

Market driver

  • Special regulatory designations
  • For a full, detailed list, view our report

Market challenge

  • High cost of therapy
  • For a full, detailed list, view our report

Market trend

  • Rise in development of combination therapies
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Types of CLL
  • Symptoms
  • Diagnosis
  • Staging
  • Management
  • Key buying criteria

PART 06: Pipeline analysis

  • Acalabrutinib
  • TG-1101 + ibrutinib
  • TGR-1202
  • Venetoclax + obinutuzumab
  • Venetoclax + rituximab
  • REVLIMID
  • Duvelisib

PART 07: Market landscape

  • Global CLL therapeutics market
  • Total addressable market for global CLL therapeutics
  • Five forces analysis

PART 08: Market segmentation by ROA

  • Oral
  • Parenteral

PART 09: Market segmentation by type of molecule

  • Small molecules
  • Biologics

PART 10: Geographical segmentation

  • Global CLL therapeutics market by geographical segmentation 2015-2020
  • CLL therapeutics market in Americas
  • CLL therapeutics market in EMEA
  • CLL therapeutics market in APAC

PART 11: Market drivers

  • Special regulatory designations
  • Recent drug approvals
  • Application for expanded indication approvals
  • Increase in patient pool

PART 12: Impact of drivers

PART 13: Market challenges

  • High cost of therapy
  • Availability of chemotherapy and off-label drugs
  • Adverse effects of drugs
  • Stringent regulatory guidelines

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Joint ventures and partnerships
  • Patient assistance programs
  • Rise in development of combination therapies
  • Growing public awareness
  • PART 16: Vendor landscape
  • Competitive scenario
  • Market share analysis 2015
  • F. Hoffmann-La Roche
  • AbbVie
  • Teva Pharmaceuticals
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • Other prominent vendors

PART 17: Appendix

  • List of abbreviations

PART 18: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Timeline of development of leukemia drugs
  • Exhibit 03: Snapshot of CLL
  • Exhibit 04: Types of CLL
  • Exhibit 05: Main diagnostic procedures to determine presence of CLL
  • Exhibit 06: Other diagnostic procedures to determine presence of CLL
  • Exhibit 07: Rai stages of CLL
  • Exhibit 08: Binet stages of CLL
  • Exhibit 09: Management of CLL
  • Exhibit 10: Key buying criteria for CLL drugs
  • Exhibit 11: Pipeline portfolio: Global CLL therapeutics market
  • Exhibit 12: Percentage share of drug candidates by stage of development 2015
  • Exhibit 13: Global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 14: Total addressable market for global CLL therapeutics market 2015-2020 ($ billions)
  • Exhibit 15: Five forces analysis
  • Exhibit 16: Segmentation of global CLL therapeutics market by ROA 2015
  • Exhibit 17: Segmentation of global CLL therapeutics market by type of molecule 2015
  • Exhibit 18: Segmentation of global CLL therapeutics market based on geography 2015
  • Exhibit 19: Segmentation of global CLL therapeutics market based on geography 2020
  • Exhibit 20: Global CLL therapeutics market by geography 2015-2020 ($ millions)
  • Exhibit 21: Global CLL therapeutics market by geography 2015-2020
  • Exhibit 22: CLL therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 23: CLL therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 24: CLL therapeutics market in APAC 2015-2020 ($ millions)
  • Exhibit 25: Global CLL therapeutics market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 26: Population aged 60 years and over: World, developed, and developing regions (millions)
  • Exhibit 27: Impact of drivers
  • Exhibit 28: Cost of therapy for CLL
  • Exhibit 29: Impact of drivers and challenges
  • Exhibit 30: SWOT: MabThera
  • Exhibit 31: SWOT: Imbruvica
  • Exhibit 32: SWOT: Treanda
  • Exhibit 33: SWOT of Zydelig
  • Exhibit 34: F. Hoffmann-La Roche: YoY growth and revenue generated from total product sales of MabThera/Rituxan (oncology indication) 2013-2015 ($ billions)
  • Exhibit 35: MabThera/Rituxan geographic segmentation by revenue 2015
  • Exhibit 36: F. Hoffmann-La Roche: Key takeaways
  • Exhibit 37: AbbVie: Key takeaways
  • Exhibit 38: Teva Pharmaceuticals: YoY revenue and growth rate of Treanda 2013-2015 ($ millions)
  • Exhibit 39: Teva Pharmaceuticals: Key takeaways
  • Exhibit 40: Johnson & Johnson: YoY revenue comparison of Imbruvica (Global) 2013-2015 ($ millions)
  • Exhibit 41: Johnson & Johnson: YoY revenue comparison of Imbruvica (US) 2013-2015 ($ millions)
  • Exhibit 42: Johnson & Johnson: YoY revenue comparison of Imbruvica (ROW) 2013-2015 ($ millions)
  • Exhibit 43: Johnson & Johnson: Geographic segmentation of Imbruvica 2015
  • Exhibit 44: Johnson & Johnson: Key takeaways
  • Exhibit 45: Gilead Sciences: YoY revenue and growth rate of Zydelig 2013-2015 ($ millions)
  • Exhibit 46: Gilead Sciences: Key takeaways
  • Exhibit 47: Novartis: Key takeaways
Back to Top